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A B S T R A C T   
Nano-formulations that are responsive to tumour-related and externally-applied stimuli can offer improved, site- 
specific antitumor effects, and can improve the efficacy of conventional therapeutic agents. Here, we describe the 
performance of a novel stimulus-responsive nanoparticulate platform for the targeted treatment of prostate 
cancer using sonodynamic therapy (SDT). The nanoparticles were prepared by self-assembly of poly(L-glutamic 
acid-L-tyrosine) co-polymer with hematoporphyrin. The nanoparticulate formulation was characterized with 
respect to particle size, morphology, surface charge and singlet oxygen production during ultrasound exposure. 
The response of the formulation to the presence of cathepsin B, a proteolytic enzyme that is overexpressed and 
secreted in the tumour microenvironment of many solid tumours, was assessed. Our results showed that digestion 
with cathepsin B led to nanoparticle size reduction. In the absence of ultrasound, the formulation exhibited 
greater toxicity at acidic pH than at physiological pH, using the human prostate cells lines LNCaP and PC3 as 
targets. Nanoparticle cellular uptake was enhanced at acidic pH – a condition that was also associated with 
greater cathepsin B production. Nanoparticles exhibited enhanced ultrasound-induced cytotoxicity against both 
prostate cancer cell lines. Subsequent proof-of-concept in vivo studies demonstrated that, when ectopic human 
xenograft LNCaP tumours in SCID mice were treated with SDT using the systemically-administered nano-
particulate formulation at a single dose, tumour volumes decreased by up to 64% within 24 h. No adverse effects 
were observed in the nanoparticle-treated mice and their body weight remained stable. The potential of this 
novel formulation to deliver safe and effective treatment of prostate cancer is discussed.   
1. Introduction 
Sonodynamic therapy (SDT) employs low-intensity ultrasound in 
combination with sensitizing agents, such as porphyrins, for the gener-
ation of cytotoxic reactive oxygen species (ROS) and the subsequent site- 
specific ablation of tumours [1]. Ultrasound can be applied locally, 
either extracorporeally or by endoscopic / transrectal intervention, and 
the acoustic waves, at frequencies between 0.5 and 2 MHz, are trans-
mitted efficiently through tissue to irradiate the target tumour, as long 
as there is a suitable “acoustic window” between the ultrasound trans-
ducer and the target [2]. It has been reported that, when tissue is 
exposed to ultrasound, at this relevant frequency range, gas micro- and 
nano-bubbles are nucleated, a phenomenon known as cavitation. Under 
ultrasound exposure, these bubbles oscillate and eventually collapse 
(inertial cavitation), producing light, a phenomenon known as sonolu-
minscence [3,4]. Since many sonosensitisers are also photosensitisers, it 
has been suggested that the production of ROS during SDT is due to 
photoexcitation of the sensitizer by sonoluminescence (Fig. 1a). The 
latter excites the sensitizing agent and this phenomenon results in the 
production of either cytotoxic singlet oxygen (1O2) by intersystem 
crossing and direct energy transfer (Type II reactions) or to the gener-
ation of other cytotoxic free radicals by electron transfer to other 
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molecular species such as biological molecules (Type I reactions) [5]. 
SDT does not require the systemic administration of potentially toxic 
agents and the cytotoxic effect tends to be limited to the target tissue as 
it is dependent on exposure to ultrasound energy above a given 
threshold. Further highlighting the benefits of SDT, no cancer cell 
population has shown resistance to therapy-triggered ROS production or 
their cytotoxic effects [6]. This is particularly important, given the as yet 
unresolved issues of radiation and chemotherapy associated resistance. 
A number of relatively recent reports have demonstrated that the 
efficacy and translational potential of SDT, for a broad range of cancers, 
can be augmented with nanotechnology. Various nanoparticulate de-
signs have been employed to serve as carriers of sensitizers, such as 
hematoporphyrin and its derivatives. The relevant preclinical studies 
have shown that these formulations can improve the antitumour effect 
of sensitizers in response to ultrasound in a multifunctional manner. 
Apart from improving the bioavailability and tumour accumulation of 
relatively hydrophobic sensitizers, nanoformulation has the potential to 
potentiate sonoactivation of sensitizers, improve cellular uptake within 
tumours and even co-carry agents with synergistic antitumour effects, 
such as immunoadjuvants or immune checkpoint inhibitors. Polymeric 
nanoparticles or micelles have been designed as carriers for the systemic 
administration of hydrophobic sensitizers, such as hematoporphyrin 
[6]. Nanoparticulate formulations with porous structures have been 
developed to seed bubble formation upon ultrasound irradiation and 
augment sonoluminescence-induced excitation of the sensitizing agent 
for the production of ROS [7,8]. 
Multi-stimulus-responsive anticancer nano-formulations can pro-
mote drug release and activation within the target tumour, facilitate 
cellular uptake, as well as improve the therapeutic efficacy of drugs. In 
solid tumours disease-specific stimulation can be provoked by the well- 
known distinctive characteristics of the tumour microenvironment, such 
as hypoxia, the acidic pH, the enhanced permeability and retention 
(EPR) effect, the abundance of proteolytic enzymes, and the over-
expression of particular cell membrane antigens or proteolytic factors. 
These endogenous, tumour-specific characteristics provide valuable 
tools for the design of formulations with enhanced activity in the tumour 
microenvironment. Polyglutamate (PGA) is among the biodegradable 
polymers that have been successfully used in drug delivery systems for 
cancer, mainly as PGA-drug conjugates [9]. Interestingly, PGA can be 
digested by cathepsin-B, which is a lysosomal protease that is hyper- 
secreted into the tumour microenvironment of many solid tumours 
and we and others have demonstrated that this can be exploited in 
targeted therapeutic approaches [10,11]. 
Below, we describe the development and initial testing of a nano-
particulate hematoporphyrin-carrying formulation, based on a co-poly-
mer of glutamate and tyrosine. The nanoparticles are designed to 
improve the delivery of hematoporphyrin to prostate tumours, its 
diffusion throughout the dense tumour mass and its efficacy in aug-
menting ultrasound-induced targeted toxicity. We report on the 
response of the formulation to particular characteristics of the prostate 
tumour microenvironment and its efficacy in mediating SDT-based 
cytotoxic effects under these conditions in vitro. In addition, proof-of- 
Fig. 1. Illustration of (a) the suggested mechanism of the cytotoxic effect induced by SDT: cavitation bubbles formed upon ultrasound irradiation implode and emit 
sonoluminescence that excites the sensitizer leading to the production of cytotoxic ROS, (b) self assembly of the co-polymer with hematoporphyrin, via hydrophobic 
and π-π interactions, for the formation of HPNP nanoparticles, (c) cathepsin B in the tumour extracellular environment digests HPNPs, leading to the formation of 
smaller particles, improved diffusion within the tumour mass and improved cellular uptake, and (d) HPNP digestion by cathepsin B in the endo-lysosome can promote 
the incorporation of free hematoporphyrin or amphiphilic hematoporphyrin complexes in the lysosomal membrane, the sensitization of the latter and the subsequent 
lysosome collapse upon ultrasound irradiation, due to sonochemical effects. 
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concept studies were performed in order to demonstrate nanoparticle- 
mediated SDT efficacy using an ectopic human prostate cancer xeno-
graft model in mice. 
2. Materials and methods 
2.1. Co-polymer digestion with Cathepsin-B 
The poly(L-glutamic acid-L-tyrosine) 4:1, sodium salt (PGATyr) 
(MW: 20–50 kDa; Sigma-Aldrich, UK) (2 mg/mL) was incubated with 
cathepsin-B (from human placenta; Sigma-Aldrich, UK) (0.6 units/mL) 
in pH 6.4 and pH 7.4 solutions, for 3 days, in an orbital incubator, at 
37 ◦C. 15 μL aliquots were obtained from the incubating mixture every 
24 h and were stored at − 20 ◦C until use. Samples were treated with tris- 
glycine sodium dodecyl sulphate (SDS) sample buffer (Novex by Life 
Technologies, UK) as recommended by the manufacturer prior to 
gradient SDS/ polyacrylamide gradient gel electrophoresis (PAGE). 
After electrophoresis, gels were stained with 0.5% Brilliant Blue G- 
Colloidal concentrate (Sigma-Aldrich, UK) for 24 h to expose the protein 
ladder bands, followed by staining with 0.5% Alcian blue (BDH chem-
icals, UK) for visualising PGATyr. The gel bands were analyzed using 
ImageJ® for determining the progress of digestion within the course of 
3 days. 
2.2. Preparation of hematoporphyrin-containing PGATyr-based 
nanoparticles 
For the preparation of the hematoporphyrin-containing PGATyr- 
based nanoparticles (HPNPs), 10 mg of PGATyr and 5 mg of hemato-
porphyrin (HP) (Sigma Aldrich, UK) were dissolved in 10 mL of dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich, UK). The resulting mixture was 
added drop-wise to a 5 mL polyvinyl alcohol solution (PVA, MW: 124 
kDa, Sigma-Aldrich, UK) (0.5 mg/mL) and the mixture was left under 
constant stirring for 1 h. The mixture was then dialysed against water 
using dialysis tubing (MWCO: 8 kDa, Theromofisher Scientific), for 24 h. 
Subsequently, the suspension was centrifuged for 90 min at 38,000g, at 
12 ◦C using a Beckman OptimaTM L-80 ultracentrifuge. The precipitated 
pellet was suspended in 2 mL deionised water and was probe-sonicated 
for 3 min, followed by further dialysis against deionised water for 12 h. 
The dialysed solution was then sterile-filtered using a micro syringe 
filter (0.22 μm, Millex GP). The suspension was snap-frozen in a sterile 
round-bottom flask and freeze dried for 24 h. The dried sample was 
resuspended in 3 mL phosphate buffered saline (PBS) and was stored at 
4 ◦C, protected from light. 
2.3. HPNP characterization and the effect of digestion with cathepsin B 
The HP concentration in the HPNP suspension was determined using 
UV–Vis spectroscopy, by reference to a standard curve for HP, in a 1:9 
mixture of PBS and DMSO, at 534 nm. The loading efficiency of HP (or 
the yield) for the nanoparticle preparation was calculated as the weight 
ratio of the total HP in the final suspension to the quantity of initially 
added HP for the preparation of the formulation. A Zeiss EVO MA10 
Field Emission Scanning Electron Microscope was used to determine the 
nanoparticle size and morphology. The mean hydrodynamic diameter of 
the undigested and digested nanoparticles was determined by dynamic 
light scattering (DLS) using a DelsaMax PRO Particle Analyzer (Beckman 
Coulter, UK). For the preparation of the digested samples, the nano-
particles were incubated with cathepsin B (0.2 units/mL), at pH 6.4 and 
pH 7.4 (in buffered suspensions), at 37 ◦C, for 24 h. The size of nano-
particles in the presence of 10% fetal bovine serum (FBS) (Life Tech-
nologies, UK) was also measured at varying pH values. The surface 
charge of the digested and undigested nanoparticles was measured with 
electrophoretic light scattering using a Zetasizer Ultra (Malvern In-
struments, UK). 
For the quantitative analysis of ROS, except for hydrogen peroxide 
[12], free HP or HPNPs were suspended in PBS containing 10% v/v FBS. 
The suspensions were then mixed, at a 2:1 ratio, with a 1,3-diphenyliso-
benzofuran (DPBF) solution 0.4 mM in ethanol, to give a final HP con-
centration of 20 μM (12 μg/mL), in a total volume of 90 mL. The systems 
were exposed to ultrasound by immersing the ultrasound transducer of a 
Sonidel SP100 sonoporator (Sonidel Ltd., Ireland) into the 90 mL sus-
pension. Ultrasound was applied at a frequency of 1 MHz, a power 
density (intensity) of 4 W/cm2 and 25% duty cycle using a pulse repe-
tition frequency of 100 Hz. The system was protected from light. During 
ultrasound exposure, 3.5 mL aliquots were collected at different times 
(0, 1, 3 and 5 min) and were centrifuged for 1 min. The absorbance 
spectra of the supernatants were then obtained at wavelengths between 
380 and 460 nm using a UV/Vis spectrophotometer (JASCO Corpora-
tion, Japan). Since HP absorbs a considerable amount of light in the 
wavelengths of interest, the corresponding systems were also run in the 
absence of DPBF. The absorbance values of the DPBF-free samples were 
subtracted from those of the corresponding test samples (containing 
DPBF), resulting in a single absorption peak at approx. 436 nm for time 
point 0 min. 
2.4. Cell culture 
The human-derived prostate cancer cell lines LNCaP and PC3 were 
used in this study. LNCaP cells were obtained from the American Type 
Culture Collection (USA) and PC3 cells were obtained from Public 
Health England. These cell lines were selected on the basis of their 
aggressive nature and their differential PSMA expression (LNCaP: PSMA 
+ve, PC3: PSMA –ve). Both cell lines were maintained in RPMI 1640 
Medium (1×) (Life Technologies) supplemented with L-glutamine 
(GibcoBRL, UK), 10% v/v (FBS and 1% penicillin & streptomycin 
(Sigma-Aldrich, UK), at 37 ◦C, in a 5% CO2 humidified atmosphere. 
When required, single cell suspensions were prepared by treating cell 
monolayers with a 0.05% w/v solution of trypsin containing 0.02% w/v 
EDTA in PBS. Incubation at pH 6.4 was performed in growth medium by 
the 0.15% v/v addition of lactic acid 85% w/v solution. The cell viability 
was determined indirectly by measuring the relative metabolic activity 
using an MTT assay [13]. 
2.5. “Silent” toxicity of the nanoparticles and free HP 
For determining the toxicity of the nanoparticles and the free he-
matoporphyrin, in the absence of ultrasound irradiation (i.e. the “silent” 
toxicity), LNCaP and PC3 cells were seeded in wells of 96 well-plates at a 
concentration of 15 × 103 cells per well and incubated, under normoxic 
conditions, for 24 h. The growth medium was then replaced with com-
plete (including FBS) growth medium containing either HPNPs or free 
HP, at either pH 6.4 (adjusted as described in Section 2.3) or pH 7.4 
(physiological pH of growth medium), and at concentrations ranging 
from 0.01 to 20 μg/mL based on HP. The control systems contained 
growth medium at the corresponding pH, in the absence of a sensitizing 
agent. Cells were incubated for 24 h after which media were removed, 
cell monolayers were washed with PBS and fresh growth medium was 
added. Plates were then incubated for a further 24 h and cell viability 
was determined using the MTT assay. 
2.6. Intracellular and extracellular cathepsin B activity 
LNCaP cells were seeded in wells of 24 well-plates at a concentration 
of 6 × 104 cells per well and incubated for 24 h under normoxic con-
ditions. The growth medium was then removed, and the cells were 
incubated in a hypoxic (2 mmHg O2) environment, at pH 6.4 or pH 7.4, 
for 24 h. Intracellular and extracellular cathepsin B activity was deter-
mined using a fluorometric cathepsin B activity assay kit (Abcam, UK), 
from lysed cells and the corresponding growth medium, respectively. 
The incubation medium was collected for extracellular cathepsin B 
analysis. For the intracellular cathepsin B assessment, cells were lysed 
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using a cell lysis buffer (Abcam, UK) according to the manufacturer’s 
instructions. Subsequently, 50 μL aliquots of each cell lysate or extra-
cellular medium sample were mixed with 50 μL of cathepsin B reaction 
buffer and 2 μL of cathepsin B substrate. Samples were incubated for 45 
min and fluorescence was measured (Ex/Em = 400/505 nm). The data 
were normalised using the total protein concentration (mg/mL) in the 
cell lysate or extracellular medium samples. 
2.7. Cellular uptake studies 
To study the cellular uptake of both HP and HPNP, as well as the 
effect of cathepsin B on cellular uptake, LNCaP and PC3 cells were 
seeded in individual wells of 96-well plates at a concentration of 2 × 104 
cells per well. 24 h later, each HP formulation (free HP or HPNP) was 
added in FBS- containing growth medium (at pH 6.4 or pH 7.4) in each 
well. The free HP or HPNP concentration for each cell line was deter-
mined from the “silent” toxicity curves (Section 2.5) and that was a 
concentration with relatively low toxicity at both pH conditions. The 
effects of externally added cathepsin B and E64, a cathepsin B inhibitor, 
on cellular uptake were also examined. These molecules were added at a 
final concentration of 1.2 units/mL and 115 μg/mL, respectively. All 
systems were incubated in a hypoxic (2 mmHg O2) environment. The 
cell monolayers were then washed twice with PBS, 100 μL DMSO was 
added and the systems were incubated for 45 min, followed by pipette- 
mixing. The samples were examined using a fluorescence spectropho-
tometer, at 534 nm and 626 nm excitation and emission wavelengths, 
respectively. The fluorescence emission values were normalised against 
the control wells (in the absence of free HP or HPNPs) and on the basis of 
the cell viability in the corresponding systems determined using the 
MTT assay. 
2.8. In vitro sonodynamic effect 
LNCaP and PC3 cells were seeded in wells of 96-well plates at a 
concentration of 2 × 104 cells per well and incubated for 24 h. Cells were 
then incubated in the presence or absence of HPNP or free HP, at varying 
concentrations, based on the cell line and the pH, determined using the 
“silent” toxicity profiles as indicated. All systems were incubated in 
hypoxic (2 mmHg O2) environment for 24 h. The treatment suspensions 
were then removed, the cell monolayers were washed with PBS and 
fresh growth medium was added. Cells were treated with ultrasound at a 
frequency of 1 MHz, at varying power density (intensity) and with 
varying duty cycle (DC, %) at a pulse repetition frequency of 100 Hz for 
30 s using an SP100 sonoporator. Ultrasound gel was used to mediate 
the contact between the ultrasound transducer and the bottom of each 
well of the 96-well plates. Cells were then incubated for 24 h, under 
hypoxic conditions (2 mmHg O2) and the cell viability was determined 
using the MTT assay. 
2.9. In vivo SDT treatment 
All animals were treated humanely and in accordance with licenced 
procedures under the Animals (Scientific Procedures) Act 1986 
Amendment Regulations 2012 (ASPA 2012). In these studies a human 
prostate xenograft model (LNCaP) in immunocompromised mice was 
employed. For the induction of tumours, 5 × 106 LNCaP cells in 100 μL 
Matrigel® were injected subcutaneously into the rear dorsum of BALB/c 
SCID male mice (8 weeks old) using a 21-gauge needle. Tumour devel-
opment was monitored over time using Vernier callipers and tumour 
volume was calculated using the equation: tumour volume = length * 
width * height/2. When the tumours had reached an average size of 85 
cm3, animals were randomly distributed into 4 groups (n = 4), using the 
randomized allocation function of the Peira TM900 management soft-
ware. Following induction of anaesthesia (intraperitoneal injection of 
Hypnorm/Hypnovel), a 100 μL aliquot of the HPNPs (1.5 mg/mL based 
on HP) was injected though the tail vein at a dose of 6 mg/kg. 24 h post- 
injection, the tumours were treated with ultrasound at a frequency of 1 
MHz, a power density of 3.5 W/cm2, using a 30% duty cycle (100 Hz 
pulse repetition frequency), for 3.5 min. The ultrasound treatment pa-
rameters were optimised in the context of preliminary and previously 
published in vivo work [6,13]. Two additional groups of animals were 
treated either with the HPNPs and without ultrasound irradiation, or 
with ultrasound irradiation and injection of PBS. Control animals were 
treated with a PBS injection and tumour volume was monitored at the 
indicated times. The % increase in tumour volume was calculated 
employing the pre-treatment measurements for each group. 
2.10. Statistical analysis 
GraphPad Prism version 5 was employed for the data presentation 
and analysis, unless otherwise stated. Statistical analysis of significance 
was performed using analysis of the means and comparison of data 
groups. The latter was performed using one-way Anova with Tukey post- 
test for column statistics and two-way ANOVA with Bonferroni post-test 
for grouped statistics. Error bars represent ± the standard deviation 
(SD). A single asterisk (*) indicates p < 0.05, double asterisk (**) in-
dicates p < 0.01 and triple asterisk (***) indicates p < 0.001. 
3. Results and discussion 
3.1. Co-polymer digestion with cathepsin-B 
In a previous study, we demonstrated that PGA is efficiently cleaved 
by cathepsin B, an enzyme that is overexpressed and secreted by cancer 
cells in the tumour microenvironment [10,11]. In order to assess the 
effect of cathepsin B on the PGATyr co-polymer, the latter was incubated 
in the presence or the absence of the enzyme at 37 ◦C, at pH 6.4 and pH 
7.4, over the course of 3 days. Aliquots obtained every 24 h were sub-
jected to SDS/PAGE analysis and the image of the resolving gel is shown 
in Fig. 2a. The PGATyr samples incubated in the absence of cathepsin B 
showed a smeared profile with molecular weights extending from 70 
kDa to less than 10 kDa. The smeared profile, in terms of breadth and 
intensity, remained unchanged, even after a 3-day incubation period, in 
the absence of cathepsin B. In the presence of cathepsin B, the smeared 
profile shifted towards lower molecular weights, when samples were 
digested at pH 7.4 (Supplementary Data, Fig. S1a). At pH 6.4, the in-
tensity of the band was considerably reduced after 24 h and at that stage, 
the reduction of the mean molecular weight (MW) was 11-fold higher (p 
< 0.001) that that at pH 7.4 (Supplementary Data, Fig. S1). Also, the co- 
polymer appeared to be fully digested below 17 kDa after 48 h at pH 6.4. 
In addition to verifying that the PGATyr remained stable in the absence 
of cathepsin B over 3 days, these results also verified that the co- 
polymer, similarly to PGA, was sensitive to cathepsin B and that diges-
tion was more efficient at acidic pH, which represents the conditions of 
the tumour microenvironment [14]. 
3.2. Nanoparticle characterization and the effect of digestion with 
cathepsin B 
The HPNP structure formation was based on the self-assembly of the 
amphiphilic PGATyr copolymer and its complexation with HP (Fig. 1b), 
which was effectively supported via hydrophobic and π-π interactions 
with the tyrosine aromatic side chain of the copolymer [15]. The 
preparation protocol and the component ratio applied in this study 
resulted in a 21.3 ± 0.6% (n = 9) entrapment of HP (yield). Images from 
scanning electron microscopy (SEM) showed nanoparticles with glob-
ular morphology (Fig. 2b). The mean hydrodynamic diameter of the 
undigested nanoparticles, determined using DLS, was 55 nm, with 
nanoparticle diameter ranging from 31 nm to 96 nm (n = 5) (Fig. 2c) and 
this was confirmed by the SEM analysis. The mean nanoparticle hy-
drodynamic diameter was also determined in the presence of serum and 
it was found to be increased by 5 nm (Supplementary Data, Fig. S2), 
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potentially due to the formation of a soft protein corona [16]. Having 
demonstrated that cathepsin B efficiently induces digestion of the 
PGATyr copolymer, it was expected that the presence of the proteolytic 
enzyme would also induce HPNP digestion resulting in the formation of 
smaller particles/complexes and the release of free hematoporphyrin. In 
order to investigate the effect of cathepsin B on the HPNPs, the formu-
lation was incubated with cathepsin B, at pH 7.4 and pH 6.4, at 37 ◦C, for 
24 h. Digested samples were analyzed using DLS and compared to the 
undigested formulation (Fig. 2c). The mean diameter of the nano-
particles digested with cathepsin B at pH 6.4 was 31 nm, with diameters 
ranging between 23 and 55 nm, while the corresponding mean diameter 
of the nanoparticles digested at pH 7.4 was 23 nm, with diameters 
ranging between 18 and 31 nm and 2–3 nm. The data in Fig. 2c 
demonstrate that digestion of nanoparticles with cathepsin B for 24 h 
resulted in 44% and 58–95% decrease of nanoparticle size, at pH 6.4 and 
pH 7.4, respectively. Surprisingly, the level of digestion at physiological 
pH was higher than that at pH 6.4 (p > 0.05), despite the fact that the co- 
polymer is digested more efficiently at pH 6.4, as shown in Fig. 2a. 
Importantly, for digesting the nanoparticulate assembly, the endopep-
tidase activity of the enzyme is sterically more essential than the 
exopeptidase activity for facilitating effective and rapid digestion. 
Interestingly, although the optimum pH for the exopeptidase activity of 
cathepsin B is 5, the endopeptidase activity increases with increasing 
pH, due to the disruption of the ionic bonds that stabilize binding of the 
occluding loop to the enzyme body, and the pH optimum is found to be 
at neutral values [17]. This occurrence can rationalize the more efficient 
digestion of nanoparticles at pH 7.4 than at pH 6.4. Another explanation 
is related to the stronger intramolecular hydrogen bonding between the 
more protonated carboxyl side chains and the polymer backbone at pH 
6.4, compared to pH 7.4 [18]. These stronger intramolecular hydrogen 
bond interactions at pH 6.4 can prevent the dissociation /release of 
polymer fragments from the main nanoparticulate assembly. On the 
contrary, the more negatively ionized form of the digestion-produced 
polymer fragments and nanoparticulate assemblies at pH 7.4 result in 
stronger electrostatic repulsion between them [18]. These phenomena 
can also explain the appearance of a peak at 3 nm diameter for pH 7.4, 
which indicates the detection of small distinctive fragments or polymer- 
hematoporphyrin aggregates. 
It is worth noting that higher concentrations of cathepsin B in the 
afore-mentioned systems could have potentially resulted in improved 
levels of digestion and the formation of smaller particles. However, 
when higher cathepsin B concentrations were used in these experiments, 
a precipitate of aggregates was formed upon extensive digestion and the 
subsequent production of highly hydrophobic fragments that distorted 
DLS measurements. Due to the formation of hydrophobic fragments 
upon digestion with the enzyme, the systems in the following experi-
ments were set up in the presence of FBS, which prevented aggregation 
and precipitation of the fragments. The presence of serum is also a more 
representative condition of biological systems, as distinct from serum- 
free experimental settings. 
Overall, the results demonstrate the efficient cathepsin B-induced 
digestion of nanoparticles into smaller particles (Fig. 1c), which 
potentially translates to an improved distribution of the sensitizer in 
dense tumour structures. This is particularly important considering the 
impaired nanoparticle diffusion throughout dense tumour masses, 
which mainly results from the high-interstitial fluid pressure and the 
dense network of collagen fibers [19]. These results suggest that, upon 
tumour accumulation through the EPR effect, the nanoparticles can be 
digested into smaller particles by the increased pericellular cathepsin B 
secreted by malignant cancers. This may subsequently enhance particle 
diffusion throughout the dense tumour mass upon extravasation, pre-
venting excess sequestration and entrapment in the perivascular space. 
Cathepsin B has a pH optimum of 4.5 to 5.5, and it is expected that 
complete nanoparticle digestion and subsequent hematoporphyrin 
release occurs within the lysosomes. This occurrence can promote the 
incorporation of free hematoporphyrin or amphiphilic hematoporphyrin 
complexes in the lysosomal membrane, the sensitization of the latter and 
the subsequent lysosome collapse upon ultrasound irradiation, due to 
Fig. 2. a. SDS-PAGE for PGATyr co-polymer digested by cathepsin B at 37 ◦C over 3 days, at pH 6.4 and pH 7.4. b. SEM image of the hematoporphyrin-carrying 
PGATyr-based nanoparticles (HPNPs). A size bar of 200 nm is indicated in green. c. Size distribution of undigested HPNPs (control), HPNPs digested at pH 6.4 
and pH 7.4, for 24 h. The data are the average of size distribution from multiple measurements (n = 5) and the X-axes is at log10 scale. The p values show the 
significant difference between the mean diameter of the digested samples and the control (undigested). d. Zeta potential of the undigested and digested HPNPs at pH 
6.4 and pH 7.4. The p value show the significant difference between digested and undigested samples at pH 7.4. Error pars represent the SEM, **p < 0.001 and ***p 
< 0.0001 (n = 5). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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sonochemical effects (Fig. 1d) [20]. It has previously been shown that 
lysosomal collapse can significantly decrease cytoplasmic pH, which can 
lead to apoptosis [21]. Hence, it is hypothesized that this is one of the 
potential mechanisms of the treatment modality described in this study 
and the effect is supported by the responsiveness of the nanoparticulate 
formulation to cathepsin B. 
The surface potential of the nanoparticles was − 24.76 ± 1.76 mV at 
pH 7.4 and − 22.54 ± 2.01 at pH 6.4 (Fig. 2d). The lower absolute zeta 
potential of the undigested particles at pH 6.4, compared to physiolog-
ical pH, is explained by the higher protonation level of the glutamate 
carboxylic acid side chains and the carboxylic acid residues of hema-
toporphyrin. The data in Fig. 2d indicate that digestion with cathepsin B 
for 24 h decreased the surface potential to − 13.80 ± 1.63 and to − 18.36 
± 1.41 at pH 7.4 (p < 0.01) and pH 6.4 (p > 0.05), respectively. 
Importantly, the reduction of negative charge upon digestion can lessen 
charge repulsion between the nanoparticles and cellular membranes for 
improving cellular uptake. 
The typical production of cytotoxic ROS (except for hydrogen 
peroxide) during sonodynamic activation using the nanoparticulate 
formulation was demonstrated using DPBF degradation induced by ROS 
and confirmed by the consequent decrease in absorbance overtime, 
within the course of 5 min. For comparative purposes, the production of 
ROS was also evaluated in the presence of free hematoporphyrin and in 
the absence of any sensitizing agent, i.e. only upon ultrasound irradia-
tion. The data in Fig. 3 demonstrate that, upon ultrasound exposure, the 
nanoformulation has comparable performance with the free hemato-
porphyrin (p > 0.05), in terms of ROS production, and this is indicative 
of an efficient SDT-induced antitumour effect. 
3.3. “Silent” dose-response and the effect of pH 
In order to identify the maximum nanoparticle concentration with 
low cytotoxicity for subsequent cellular uptake studies and to clearly 
demonstrate ultrasound-induced cytotoxicity, i.e. a sonodynamic effect, 
in experiments to follow, it was essential to determine the toxicity 
profile of the nanoparticles and compare it with that of free hemato-
porphyrin, at physiological and acidic conditions. This would allow us, 
in each case, to use HPNP and free HP concentrations with minimal toxic 
effect in the absence of ultrasound (“silent” effect). LNCaP and PC3 cells 
were treated with increasing concentrations of the free sensitizer or the 
nanoparticulate formulation, ranging from 0.01–20 μg/mL based on HP 
concentration. All systems were undertaken in the presence of FBS, 
therefore aggregation and subsequent precipitation of free HP was 
avoided. Results in Fig. 4 demonstrate that, for LNCaP cells, the free and 
nanoparticulate HP elicited “silent” cytotoxicity at concentrations 
higher than 10 μg/mL at pH 7.4. The corresponding toxicities at pH 6.4 
were significantly increased, with the highest comparable concentration 
of relatively low cytotoxicity identified at 5 μg/mL. The “silent” toxicity 
profile for PC3 cells was different. The free sensitizer did not have any 
cytotoxic effect at concentrations up to 20 μg/mL, while the nano-
particulate sensitizer showed significant toxicity at concentrations 
higher than 3 μg/mL and 5 μg/mL, for pH 6.4 and pH 7.4, respectively. 
Overall, these results demonstrate that the nanoparticulate formulation 
had increased cytotoxic effect at acidic pH for both cell lines. This is 
particularly important considering that improved cytotoxicity at the 
tumour acidic conditions can confine and potentiate the ablation effect 
within the tumour mass, reducing the effects on healthy surrounding 
Fig. 3. Spectra indicating the time-dependent decrease of DPBF absorbance induced by ROS, in ultrasound-exposed: a.sensitizer-free solvent mixture, b. free he-
matoporphyrin solution and c. HPNP suspension. Curves are formed using the mean values, with n = 3. c. Percentage of absorbance decrease at 436 nm compared to 
the ultrasound-untreated corresponding samples (n = 3). 
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tissues. 
3.4. The effect of pH and cathepsin B on cellular uptake 
The nanoparticulate formulation developed in this study is designed 
to respond to features of the tumour microenvironment, such as the 
acidic tumour interstitium and cathepsin B. Cathepsin B is among the 
proteolytic enzymes that are abundant in the microenvironment of 
malignant tumours and its expression and secretion by cancer cells are 
extensively regulated on the basis of the interstitial pH. Examining the 
intracellular and secreted levels of this enzyme for LNCaP cells was an 
essential step based on the aim to exploit cathepsin B for improving the 
performance of our therapeutic platform in SDT. Considering that 
cathepsin B secretion in tumours is triggered by hypoxia [22], the 
incubations were carried out under hypoxic conditions, at 2 mmHg O2. 
The results in Fig. 5a and b demonstrate that, for LNCaP cells, at pH 6.4, 
the levels of extracellular and intracellular cathepsin B were elevated by 
35% and 61%, respectively, at acidic pH, when compared to pH 7.4. The 
cellular uptake of the nanoparticles, at a final concentration of 5 μg/mL 
with respect to HP concentration, for both pH conditions was deter-
mined. HPNP uptake by LNCaP cells was increased by 75% for pH 6.4 
when compared with pH 7.4 (Fig. 5c) and this corresponds with the 
increase in cathepsin B at this pH (Fig. 5b). Although, this is not robust 
evidence of direct correlation of cathepsin B with nanoparticle cellular 
uptake, it is suggestive that the levels of the proteolytic enzyme have an 
effect on cellular uptake of the PGATyr-based nanoparticles. This result 
may also be attributed to the expected increased protonation of the 
glutamate residue side chains at acidic conditions that would lead to 
Fig. 4. “Silent” cytotoxicity of free hematoporphyrin (Free HP) and HP-containing PGATyr nanoparticles (HPNPs), at pH 7.4 and pH 6.4, for LNCaP (a) and PC3 (b) 
cells. The concentrations used in following experiments for pH 6.4 and pH 7.4, for each cell line, are indicated in red. (*p < 0.05 and ***p < 0.001, n = 3). The p 
values show the significance of difference between samples incubated at pH 6.4 and those at pH 7.4. (For interpretation of the references to colour in this figure 
legend, the reader is referred to the web version of this article.) 
Fig. 5. Levels of extracellular (a) and 
intracellular (b) cathepsin B after 24 h 
incubation of LNCaP cells at hypoxic 
conditions, at pH 7.4 and pH 6.4. 
Cellular uptake (c) after incubation of 
LNCaP cells with nanoparticles (HPNPs) 
for 24 h, at the corresponding condi-
tions. Cellular uptake after incubation 
of LNCaP (d) and PC3 (e) cells with free 
hematoporphyrin (Free HP), nano-
particles (HPNPs), nanoparticles with 
cathepsin B (HPNPS+CB) and nano-
particles with chathepsin B inhibitor 
E64 (HPNPs+E64) for 24 h, at acidic 
and hypoxic conditions. **p < 0.001 
and ***p < 0.0001 (n = 4).   
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reduction of the absolute zeta potential, facilitating improved cell 
internalization. 
Since precedence in the literature suggested improved cellular up-
take of PGA-based nanoparticles that were digested with cathepsin B 
[10], the role of cathepsin B, in this context, was further investigated. 
The uptake of HPNPs by LNCaP cells was examined at pH 6.4 in the 
presence of extra cathepsin B added in the cell incubation systems and in 
the presence of E-64, a cathepsin B inhibitor. The corresponding systems 
were also set up to examine the effect of supplemental cathepsin B and E- 
64 on HPNP uptake by PC3 cells, at pH 6.4. While the experiment was 
carried out using a concentration of 5 μg/mL for the free HP and HPNP 
in the LNCaP experiment, for the PC3 experiment, the free HP or HPNP 
were used at a final concentration of 3 μg/mL. Data in Fig. 5d demon-
strate that the presence of added cathepsin B and E-64 in the incubation 
systems resulted in 24% and 26% reduction, respectively, in HPNP 
cellular uptake for the LNCaP cells. Although the presence of cathepsin B 
had negative impact on cellular uptake for LNCaP cells, in the case of 
PC3 cells, the supplemental cathepsin B significantly (p < 0.01) 
increased nanoparticle uptake by 17%, while E-64 decreased the uptake 
by 13% (Fig. 5e). In overall terms these results support the suggestion 
that cathepsin B is playing some role in enhancing the uptake of the 
payload by the cells. Importantly, the addition of the cathepsin B in-
hibitor E-46 did partially inhibit enhanced uptake and we suggest that 
cathepsin B is certainly involved in the mechanism by which the HPNP 
uptake is enhanced. In addition, results in Fig. 5 demonstrate that for 
both cell lines, the nanoparticulate platform significantly increased 
cellular uptake of hematoporphyrin, since the uptake of the free agent 
was 54% and 35% lower for LNCaP and PC3 cells, respectively, when 
compared to the uptake of the nanoparticulate system. 
In order to properly interpret the results in Fig. 5c, d and e, it is 
important to take into consideration that LNCaP cells express prostate 
specific membrane antigen (PSMA) whereas PC3 cells do not. Similarly 
to cathepsin B, PSMA exhibits glutamate carboxypeptidase activity [23] 
and, in principle, it leads to degradation of PGA. Based on these results 
and considering the similar in vitro cathepsin B expression profiles of 
LNCaP and PC3 cells [24], it is hypothesized that the supplemental 
cathepsin B led to increased nanoparticle degradation, which was 
enough to have a detectable positive impact on cellular uptake for the 
PSMA-lacking PC3 cells. For the PSMA-expressing LNCaP cells, at the in 
vitro conditions employed in this study, the presence of additional 
cathepsin B did not support cellular uptake. This suggests that some 
other aspect, possibly PSMA-induced degradation, is contributing to the 
enhanced uptake of HPNP. The reduction of cellular uptake in the 
presence of cathepsin B could be a result of the enzymatic action of the 
latter against PSMA. Interestingly, the protease (carboxypeptidase) 
domain of PSMA contains a functional and critical glutamate residue, 
which can be potentially cleaved by cathepsin B, and subsequently 
inhibit the overall nanoparticle size reduction [25]. Efforts are currently 
underway in order to further explore these interesting observations. 
Nevertheless, it must be considered that both cathepsin B and PSMA are 
indigenous molecules and they are variably expressed throughout 
prostate tumours; hence, the way these molecules interact and the effect 
of their interaction on nanoparticle cellular uptake cannot be regulated. 
3.5. In vitro sonodynamic effect 
Having determined that the appropriate nanoparticle concentrations 
for examining the sonodynamic effect were 10 μg/mL and 5 μg/mL, at 
pH 7.4 and pH 6.4, respectively, LNCaP cells were treated with the 
HPNPs and the treatment was combined with ultrasound exposure 24 h 
later (Fig. 6a). Fig. 6b depicts the effect of HPNPs, at pH 7.4, without and 
with ultrasound treatment at varying ultrasound parameters, yielding 
Fig. 6. a. In vitro treatment protocol. b. % cell viability of LNCaP cells treated with in the absence (No HPNPs) and the presence of nanoparticles (HPNPs), at 10 μg/ 
mL HP concentration, without (No US) and with ultrasound exposure (30 s) at different parameters. c. Cell viability of LNCaP cells treated with no agent (control), 
free hematoporphyrin (free HP) and nanoparticles (HPNPs), at 5 μg/mL HP concentration, at pH 6.4, without (No US) and with ultrasound (US) exposure at 3 W 
cm− 2, 50% DC, for 30 s. d. Cell viability of PC3 cells with no treatment (control), ultrasound only exposure (US), hematoporphyrin nanoparticles nanoparticles at 3 
μg/mL (for pH 6.4) and 5 μg/mL (for pH 7.4) HP concentration (HPNPs), and hematoporphyrin nanoparticles in combination with ultrasound (SDT), at pH 6.4 and 
pH 7.4. Ultrasound exposure was at 3 W cm− 2, 50% DC, for 30 s. (*p < 0.05, ***p < 0.001, n = 4) For b. and d.:The p values show the significance of difference 
between samples incubated in the presence and the absence of nanoparticles, under ultrasound exposure. 
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total provided energy between 26 and 60 J/cm2. The results also 
demonstrate the effect of ultrasound exposure on this cell line in the 
absence of the formulation. The results demonstrate that sonodynamic 
treatment, i.e. ultrasound treatment in combination with the formula-
tion, reduced cell viability by 91–93%, at the ultrasound conditions 
employed, while exposure to ultrasound alone and the nanoparticles in 
the absence of ultrasound had no effect on cell viability. This dramatic 
sonodynamic effect, with no individual ultrasound-induced or 
nanoparticle-induced “silent” toxicity effects, demonstrates the poten-
tial of this technology to achieve efficient and site-specific tumour 
treatment. In a recent study, Huang and co-workers developed a rela-
tively complex hematoporphyrin-containing nanoparticulate thera-
nostic platform and demonstrated the sonodynamic potential of that 
system using human breast cancer and lung cancer cell lines [26]. In that 
study, the treatment, in its non-targeted form, elicited up to approxi-
mately 65% in vitro toxicity, when irradiated with ultrasound; however, 
the “silent” effect of the non-targeted form of the nanoparticulate he-
matoporphyrin was not indicated in the study results, hence it is not 
possible to appreciate the potential of that system in sonodynamic 
therapy. The results in Fig. 6b demonstrate a clear ultrasound-induced 
HPNP toxicity, i.e. a clear sonodynamic effect, with no toxicity at the 
same concentration in the absence of ultrasound. 
The sonodynamic performance of the HPNPs against LNCaP cells was 
also investigated at pH 6.4. Results in Fig. 6c demonstrate that ultra-
sound irradiation, at 3 W/cm2 and 50% DC for 30 s, potentiated the 
cytotoxicity of HPNPs by 29%. The free hematoporphyrin, at the cor-
responding concentration, resulted in 20% toxicity, which was not 
significantly elevated with the application of ultrasound. This finding 
indicated that, unlike the nanoparticulate hematoporphyrin, the free 
sensitizer did not elicit a sonodynamic effect under these conditions and 
this outcome can be potentially attributed to the reduced cellular uptake 
and the potentially altered subcellular localization, which may affect 
sonodynamic-induced cytotoxicity. Essentially, this result clearly 
demonstrates the value of the proposed nanoparticulate platform for 
enhancing the sonodynamic effect of common hydrophobic sensitizers, 
such as hematopophyrin. Moreover, for in vivo and clinical applications, 
hematoporphyrin, among other sensitizers, is not recommended for 
systemic administration as a free agent, due to its hydrophobicity and 
the subsequent poor biodistribution. 
The response of PC3 to the sonodynamic treatment was similarly 
positive (Fig. 6d), even at the lower HPNP concentrations employed (5 
μg/mL for pH 7.4 and 3 μg/mL for pH 6.4), when compared with the 
LNCaP systems. Results in Fig. 6d demonstrate that exposure to ultra-
sound augmented HPNP cytotoxicity by 53% and 65%, at pH 7.4 and pH 
6.4, respectively. Based on previous reports and the results presented in 
the current study, different cell lines have shown varying responses to 
sensitizing agents, the varying formulations of the latter, and the actual 
sonodynamic treatment [3,27]. 
3.6. In vivo SDT treatment 
Having established the sonodynamic performance of the HPNP 
platform against LNCaP cells in vitro, subsequent in vivo experiments in 
SCID mice bearing LNCaP subcutaneous tumours were performed 
(Fig. 7a). The HPNP formulation was administered intravenously to the 
tumour-bearing animals at a dose of 6 mg/kg. Approximately 24 h after 
IV administration of the nanoparticles, tumours were treated with ul-
trasound. In this study, a higher ultrasound exposure dose was applied 
compared to the in vitro systems, based on previous studies and because 
of the anticipated tissue attenuation. The data obtained are shown in 
Fig. 7b and they strongly demonstrate that, while administration of 
either the HPNPs or ultrasound alone had no impact on tumour growth, 
treatment using the HPNP formulation in combination with ultrasound, 
resulted in an average of 36% reduction in tumour volume, within 24 h 
post- SDT treatment. At that point in time, tumour volume increase for 
the SDT group ranged from − 64% to 3%. Importantly, the SDT-treated 
Fig. 7. a. In vivo treatment protocol. b. Plot of % change of tumour volume treated with (i) no treatment (Control) (ii) ultrasound only (US) (iii) PGA-based 
nanoparticles carrying hematoporphyrin (HPNPs) and (iv) PGA-based nanoparticles carrying hematoporphyrin with ultrasound, i.e. sonodynamic therapy 
(HPNPs+US). Animals were administered with the formulation on Day 0 and tumours were exposed to ultrasound (3 min) on Days 1 and 2. c. The corresponding 
animal body weight increase. Error bars represent ± the SD, where n = 4. 
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tumours reached their initial pre-treatment size on day 8 (where the 
growth curve crosses the base line), when in control systems, the tumour 
size had grown beyond the 120% of the initial size. In addition, body 
weight of the animals administered with the HPNPs formulation was 
stable, while animals in the other groups (untreated and ultrasound-only 
treatment) had lost approx. 7% of their body weight by day 11, when the 
experiment was terminated (Fig. 7c). Interestingly, the animals that 
were treated with the HPNPs only, without tumour exposure to ultra-
sound, showed improved body weight increase profile, compared to the 
other control systems, despite the lack of tumour growth delay. This is a 
development potentially associated with reduced level of metastatic 
progression and it requires further investigation. In this study, the 
administered formulation dose, based on hematoporphyrin concentra-
tion, was at similar level and not any higher than the doses used in 
previous studies [6]. Although, the formulation improved the body 
weight profile of the animals post-treatment and no adverse effects were 
observed, future dose escalation studies, accompanied by toxicological 
analyses, would be necessary in order to determine the dose that can be 
used to optimize SDT using this formulation. 
In a series of recent reports in the literature, SDT has been evaluated 
for the treatment of a number of different human cancers in preclinical 
studies, including breast, pancreatic, melanoma, and colon cancer, 
while no relevant preclinical study has been published for evaluating the 
effect of this therapeutic approach in the treatment of prostate tumours. 
Among those studies, sensitizing agents, formulated in varying micro- or 
nano-particulate systems, were employed. The formulations have 
included microbubbles (2–3 μm in diameter) with individual molecules 
of a sensitizer stably attached on their surface [28–31], sensitizer‑gold 
nanoparticle conjugates [32], and polymeric nanoparticles containing 
the sensitizing agent [6]. In some of those studies, the sonodynamic 
treatment was combined with a chemotherapeutic agent, in order to 
enhance the toxicity of the latter in a site-specific manner and provide an 
improved therapeutic result based on SDT [33,34]. Regardless of the 
type of cancer, the sensitizer or the formulation design, the ever- 
increasing published preclinical studies have clearly demonstrated 
that SDT affords significant tumour growth delay, with no associated 
treatment side effects. In order to highlight the improved performance of 
the formulation described here, it is worth noting that, in any of the 
previously-published studies, the extent of tumour size reduction did not 
exceed 20% using nanoparticle-based systems. The results presented 
here reveal a considerable response of LNCaP prostate tumours to SDT 
using one single dose of this easily prepared and biodegradable 
hematoporphyrin-carrying formulation. The exceptional SDT efficacy 
using this system was not only demonstrated in terms of tumour volume 
reduction rate, but also in terms of significant tumour growth delay 
(Fig. 7b). The second ultrasound exposure 48 h after administrating the 
formulation, did not contribute to any further tumour volume reduction 
and this indicated the potential elimination of the sensitizing agent from 
the tumour mass at that length of time. In future studies, the profile of 
intratumoural accumulation and retention of the formulation need to be 
characterized with biodistribution studies in order to efficiently plan the 
optimal time(s) for ultrasound exposure following IV injection. In 
addition, the tumour growth profile can be used as an indicator to 
potentially fractionate SDT treatments. In order to properly plan the 
frequency of repeated treatments, one would need to consider that STD 
results in the damage and disruption of tumour microvasculature, based 
on previous findings [35], and that damaged tumour vasculature would 
lead to poor intratumoural uptake of the formulation after systemic 
administration. In preclinical studies, the tumour growth profile, post 
treatment, is a good indicator of vasculature recovery, mainly based on 
the sustained tumour growth. Although the SDT efficacy, in most studies 
published thus far, has been examined for one single treatment (single 
dose of sensitizer formulation and single ultrasound exposure), more 
recent studies have exploited the affordability of a repeated SDT treat-
ment approach with encouraging results [36]. In the case of prostate 
cancer and based on the acoustic accessibility of the latter using either 
extracorporeal or transrectal ultrasound transducer, repeated SDT 
treatments involve a scenario that could be readily applied in a clinical 
setting and has the potential to afford complete tumour eradication, in a 
non-invasive manner and with minimal side effects. Essentially, it is 
suggested that SDT has significant potential to form the first line treat-
ment for prostate cancer patients, particularly those that do not meet the 
inclusion criteria for common locoregional ablation approaches, such as 
high-intensity focused ultrasound (HIFU), cryoablation or irreversible 
electroporation (IRE). Unlike HIFU, the low-intensity ultrasound 
employed in SDT allows patients with calcified prostate tissue to be 
eligible for this treatment. Unlike cryoablation and IRE, SDT does not 
require the insertion of electrodes or probes inside or in close proximity 
to the diseased site, allowing treatment with minimum tissue distur-
bance. For the afore-mentioned reasons, as well as based on the findings 
of the current study, prostate cancer is among the candidate recalcitrant 
malignancies, the treatment of which can significantly benefit from SDT. 
4. Conclusions 
In this work, a nanoparticle formulation was developed based on the 
self-assembly of PGATyr co-polymer with HP. The response of the 
nanoparticles to pH and cathepsin B was investigated and the corre-
sponding performance in SDT treatment was evaluated. The results 
demonstrated that digestion of the formulation with cathepsin B resul-
ted in the reduction of nanoparticle size and overall negative charge, 
potentially leading to more efficient diffusion of the nanoparticles 
throughout impermeable tumour tissues following extravasation. The 
formulation showed varied “silent” toxicity profiles in the two human 
prostate cancer cell lines, LNCaP and PC3, while the acidic pH enhanced 
the nanoparticle toxicity for both cell lines. Cathepsin B expression and 
secretion levels appeared to be proportional to cellular uptake. Sono-
dynamic treatment in vitro demonstrated a clear ultrasound–induced 
cytotoxic effect on HPNP-treated prostate cancer cells with little or no 
effect elicited by either the stimulus (ultrasound) or the formulation in 
the absence of the stimulus. The nanoparticulate formulation showed 
ultrasound-induced ROS production comparable to that of the free 
sensitizer; however, it significantly improved the sonodynamic activity 
of HP in cell-based systems, primarily as a result of improved cellular 
uptake. The in vivo study in immunodeficient mice, using the nano-
formulation, showed a mean 36% reduction in LNCaP tumour volumes 
within 24 h post-SDT treatment, with the administration of a single 
nanoparticle dose. No adverse effects were recorded and body weight 
was stable for the nanoparticle-treated animals. We anticipate that the 
nanoformulation system described in this study will open new avenues 
towards the clinical translation of SDT in the treatment of prostate 
cancer, as well as other recalcitrant cancers, the prognosis and man-
agement of which has yet to be improved with currently applied cancer 
therapies. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.jconrel.2020.11.040. 
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[2] R. Göbl, S. Virga, J. Rackerseder, B. Frisch, N. Navab, C. Hennersperger, Acoustic 
window planning for ultrasound acquisition, Int. J. Comput. Assist. Radiol. Surg. 
12 (6) (2017) 993–1001. 
M.M. Hadi et al.                                                                                                                                                                                                                                
Journal of Controlled Release 329 (2021) 76–86
86
[3] D. Costley, C. Mc Ewan, C. Fowley, A.P. McHale, J. Atchison, N. Nomikou, J. 
F. Callan, Treating cancer with sonodynamic therapy: a review, Int. J. Hyperth. 31 
(2) (2015) 107–117. 
[4] E. Beguin, S. Shrivastava, N.V. Dezhkunov, A.P. McHale, J.F. Callan, E. Stride, 
Direct evidence of multibubble Sonoluminescence using therapeutic ultrasound 
and microbubbles, ACS Appl. Mater. Interfaces 11 (22) (2019) 19913–19919. 
[5] N. Yumita, Y. Iwase, T. Watanabe, K. Nishi, H. Kuwahara, M. Shigeyama, 
K. Sadamoto, T. Ikeda, S. Umemura, Involvement of reactive oxygen species in the 
enhancement of membrane lipid peroxidation by sonodynamic therapy with 
functionalized fullerenes, Anticancer Res. 34 (11) (2014) 6481–6487. 
[6] N. Nomikou, K. Curtis, C. McEwan, B.M.G. O’Hagan, B. Callan, J.F. Callan, A. 
P. McHale, A versatile, stimulus-responsive nanoparticle-based platform for use in 
both sonodynamic and photodynamic cancer therapy, Acta Biomater. 49 (2017) 
414–421. 
[7] X. Pan, L. Bai, H. Wang, Q. Wu, H. Wang, S. Liu, B. Xu, X. Shi, H. Liu, 
Metal–organic-framework-derived carbon nanostructure augmented sonodynamic 
cancer therapy, Adv. Mater. 30 (2018), e1800180. 
[8] W. Yue, L. Chen, L. Yu, B. Zhou, H. Yin, W. Ren, C. Liu, L. Guo, Y. Zhang, L. Sun, 
K. Zhang, H. Xu, Y. Chen, Checkpoint blockade and nanosonosensitizer-augmented 
noninvasive sonodynamic therapy combination reduces tumour growth and 
metastases in mice, Nat. Com pNat Commun. 10 (1) (2019), e2025. 
[9] C. Li, Poly(l-glutamic acid)–anticancer drug conjugates, Adv. Drug Deliv. Rev. 54 
(5) (2002) 695–713. 
[10] S.P. Tarassoli, A.M. de Pinillos Bayona, H. Pye, C.A. Mosse, J.F. Callan, 
A. MacRobert, A.P. McHale, N. Nomikou, Cathepsin B-degradable, NIR-responsive 
nanoparticulate platform for target-specific cancer therapy, Nanotechnology 28 (5) 
(2017) e055101. 
[11] N. Aggarwal, B.F.Sloane. Cathepsin, B: multiple roles in cancer, Proteomics Clin. 
Appl. 8 (0) (2014) 427–437. 
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